ストックスクリーナーアプリを入手
1.41
12.42%
-0.20
アフターアワーズ：
1.47
0.06
+4.26%
Prime Medicine Inc (PRME) 最新ニュース
There is no way Prime Medicine Inc (PRME) can keep these numbers up - Sete News
Charles Schwab Investment Management Inc. Acquires 20,614 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of “Buy” from Analysts - The AM Reporter
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.38 - Defense World
Wedbush Forecasts Prime Medicine FY2029 Earnings - Defense World
Chardan Capital Forecasts Strong Price Appreciation for Prime Medicine (NYSE:PRME) Stock - Defense World
Prime Medicine (NYSE:PRME) Earns “Buy” Rating from HC Wainwright - Defense World
Why Prime Medicine Stock Was Climbing Higher This Week - Yahoo
Prime Medicine price target raised to $16 from $15 at Chardan - TipRanks
Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating - MarketScreener
Why Prime Medicine Stock Is Soaring Today - Yahoo
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year - Investing.com India
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Prime Medicine announces new α1-antitrypsin deficiency program - BioWorld MedTech
Prime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth Potential - TipRanks
H.C. Wainwright maintains Buy on Prime Medicine stock, $10 target By Investing.com - Investing.com Canada
Prime Medicine, Inc.: Innovative Prime Editing Platform Targets Unmet Medical Needs with Promising Preclinical Results - TipRanks
H.C. Wainwright maintains Buy on Prime Medicine stock, $10 target - Investing.com
Prime Medicine (NYSE:PRME) Given “Outperform” Rating at Wedbush - Defense World
Prime Medicine’s Promising Advancements in Liver-Targeting AATD Program with Prime Editing Technology - TipRanks
Prime Medicine advances AATD gene editing therapy - Investing.com India
Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating - TipRanks
Prime Medicine Advances AATD Program With Prime Editing For Potential Curative Treatment - Nasdaq
Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating - Marketscreener.com
Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive
Prime Medicine unveils program for treatment of AATD - TipRanks
Prime Medicine Advances AATD Program with Promising Preclinical Results - TipRanks
Prime Medicine Launches Preclinical Program for Liver Treatments -March 18, 2025 at 07:34 am EDT - Marketscreener.com
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewswire
Revolutionary Gene Editing Breakthrough: Prime Medicine's AATD Treatment Shows 95% Protein Restoration - StockTitan
Prime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy Rating - TipRanks
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - Benzinga
Chardan Capital Forecasts Prime Medicine FY2025 Earnings - Defense World
Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year By Investing.com - Investing.com South Africa
Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year - Investing.com
Prime Medicine Inc (PRME)’s Market Momentum: Closing Strong at 2.40, Up 4.35 - The Dwinnex
Is Prime Medicine Inc (NASDAQ: PRME) A Great Stock To Invest In? - Stocks Register
Oppenheimer & Co. Inc. Decreases Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World
HC Wainwright Expects Increased Earnings for Prime Medicine - Defense World
Citizens JMP maintains $10 target on Prime Medicine stock - Investing.com India
Prime Medicine (NYSE:PRME) Given “Buy” Rating at Chardan Capital - Defense World
Prime Medicine’s Advancements and Financial Strength Support Buy Rating Amid Promising Developments in Gene Editing and Rare Diseases - TipRanks
Prime Medicine, Inc.: Promising Gene Editing Developments and Strong Financial Position Justify Buy Rating - TipRanks
Prime Medicine’s (PRME) “Outperform” Rating Reiterated at Wedbush - Defense World
ARK Investment Management LLC Reduces Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine Reports 2024 Financial Results and Progress - TipRanks
Prime Medicine, Inc. SEC 10-K Report - TradingView
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Can Prime Medicine's $204M Cash Boost Fuel Its Gene Editing Breakthrough? Clinical Data Coming in 2025 - StockTitan
Prime Medicine (NYSE:PRME) vs. Bio-Techne (NASDAQ:TECH) Critical Analysis - Defense World
News: CMN Weekly (28 February 2025)Your Weekly CRISPR Medicine News - CRISPR Medicine News
Contrasting Prime Medicine (NYSE:PRME) and Achilles Therapeutics (NASDAQ:ACHL) - Defense World
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Prime Medicine's Gene Therapy Strategy Reshape Genetic Disease Treatment? CEO Reveals Plans - Stock Titan
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
3.01%
大文字化:
|
ボリューム (24 時間):